B‐cell very late antigen‐4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity

Natalizumab, which binds very late antigen‐4 (VLA‐4), is a potent therapy for multiple sclerosis (MS). Studies have focused primarily upon its capacity to interfere with T‐cell migration into the central nervous system (CNS). B cells are important in MS pathogenesis and express high levels of VLA‐4....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Neurol
Main Authors: Lehmann‐Horn, Klaus, Sagan, Sharon A., Bernard, Claude C.A., Sobel, Raymond A., Zamvil, Scott S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Brief Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4405474/
https://ncbi.nlm.nih.gov/pubmed/25712734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.24387
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados